Related Experiment Video
Updated: Jan 25, 2026
06:22
A Screening Method for Identification of Heterochromatin-Promoting Drugs Using Drosophila
Published on: March 12, 2020
6.3K
Drug screening in Drosophila; why, when, and when not?
Tin Tin Su1,2
1Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, Colorado.
Summary
Drug discovery requires better screening methods. This review highlights how Drosophila melanogaster can serve as a valuable model for identifying potential anti-cancer compounds, despite current limitations.
Area of Science:
- Biotechnology
- Genomics
- Pharmacology
Background:
- Thalidomide, discovered in 1953, eventually led to lenalidomide, a 2018 oncology drug bestseller.
- Advancements in understanding disease genetics and molecular biology offer new avenues for drug discovery.
- Vast chemical libraries exist, but efficient screening methods are needed to identify promising drug candidates.
Purpose of the Study:
- To review the utility of Drosophila melanogaster as a model organism for drug screening.
- To discuss the knowledge gaps and technical challenges hindering the broader adoption of Drosophila models in drug discovery.
- To identify potential solutions for optimizing Drosophila-based drug screening.
Main Methods:
- Literature review of studies utilizing Drosophila melanogaster for drug screening.
- Analysis of existing knowledge gaps and technical challenges in Drosophila drug discovery models.
- Discussion of case studies demonstrating the effectiveness of Drosophila in identifying potential therapeutics.
Main Results:
- Drosophila melanogaster has demonstrated potential as an effective model for screening compounds with therapeutic applications.
- Several examples from the literature showcase successful drug candidate identification using Drosophila.
- Identified knowledge gaps and technical challenges include limitations in high-throughput screening and complex phenotype analysis.
Conclusions:
- Drosophila melanogaster offers a powerful platform for preclinical drug screening, particularly in oncology.
- Addressing current technical challenges and knowledge gaps can significantly enhance the utility of Drosophila models.
- Further development of Drosophila-based screening strategies is crucial for accelerating the discovery of novel therapeutics.
Related Concept Videos
02:46Genetic Screens
5.6K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.6K
01:25Pharmacokinetics: Drug–Drug Interactions
410
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
410
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
155
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
155
01:26FDA Approved Drugs: Changes to Approved Drugs
248
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
248
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
462
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
462